Pseudomonas aeruginosa is a leading pathogen in healthcare-associated infections, particularly in patients with structural lung disease or indwelling devices; its capacity to develop multidrug resistance through both chromosomal and acquired mechanisms makes it a major challenge in clinical microbiology, often necessitating the use of novel beta-lactam/beta-lactamase inhibitor combinations or other last-line agents [8]. The gene discussed is LACTB; the disease is infection.